Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E20.01 EPS (ttm)2.67 Insider Own0.16% Shs Outstand1.63B Perf Week1.19%
Market Cap87.29B Forward P/E13.22 EPS next Y4.05 Insider Trans0.00% Shs Float1.63B Perf Month-1.51%
Income4.38B PEG1.81 EPS next Q0.84 Inst Own74.80% Short Float0.70% Perf Quarter-10.99%
Sales22.04B P/S3.96 EPS this Y-10.90% Inst Trans0.63% Short Ratio1.55 Perf Half Y2.18%
Book/sh8.36 P/B6.40 EPS next Y4.68% ROA4.30% Target Price59.88 Perf Year-12.79%
Cash/sh4.18 P/C12.78 EPS next 5Y11.03% ROE11.30% 52W Range46.94 - 70.05 Perf YTD-12.73%
Dividend1.60 P/FCF78.36 EPS past 5Y15.30% ROI20.20% 52W High-23.65% Beta1.10
Dividend %2.99% Quick Ratio1.40 Sales past 5Y3.30% Gross Margin70.80% 52W Low13.93% ATR1.59
Employees23700 Current Ratio1.50 Sales Q/Q8.30% Oper. Margin24.40% RSI (14)48.03 Volatility2.23% 2.95%
OptionableYes Debt/Eq0.54 EPS Q/Q128.60% Profit Margin6.50% Rel Volume1.52 Prev Close53.48
ShortableYes LT Debt/Eq0.42 EarningsOct 25 BMO Payout180.60% Avg Volume7.33M Price53.48
Recom2.50 SMA203.48% SMA50-5.92% SMA200-7.82% Volume0 Change0.00%
Oct-22-18Downgrade Citigroup Buy → Neutral
Oct-09-18Resumed Guggenheim Neutral
Aug-08-18Upgrade Atlantic Equities Underweight → Neutral
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Nov-20-18 08:25AM  Investor Expectations to Drive Momentum within Bristol-Myers Squibb, Leaf Group, SendGrid, Exantas Capital, Under Armour, and Medley Management Discovering Underlying Factors of Influence GlobeNewswire
08:12AM  Pfizer's Bavencio Phase III Study for Ovarian Cancer Fails Zacks
06:59AM  Bristol-Myers Squibb to Take Part in Evercore ISI HealthCONx Conference Business Wire
Nov-19-18 09:49AM  AstraZeneca's Imfinzi Fails in Lung Cancer Study, Stock Down Zacks
Nov-18-18 09:17AM  [$$] Why the Corporate Earnings Boom Has Failed to Lift Investors' Spirits The Wall Street Journal
Nov-16-18 02:52PM  Bristol-Myers' Opdivo Receives Positive CHMP Opinion for RCC Zacks
10:29AM  Is Paypal Holdings Inc (PYPL) A Good Investment Right Now? Insider Monkey
08:35AM  Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings Zacks
08:08AM  The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal Benzinga
Nov-15-18 04:30PM  Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab) as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma Business Wire
04:09PM  Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug Zacks
12:19PM  Bristol-Myers Squibb lays off employees in Tampa office American City Business Journals
09:16AM  Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx Zacks
Nov-14-18 05:45PM  Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know Zacks
09:07AM  Can These 2 Battered Biotech Stocks Recover? Motley Fool
08:02AM  Shire's Filing Accepted by FDA for Gattex's Label Expansion Zacks
Nov-13-18 01:17PM  Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates Zacks
07:00AM  Today's Research Reports on Trending Tickers: Nektar Therapeutics and Bristol-Myers Squibb ACCESSWIRE
Nov-12-18 04:23PM  Nektar Bounds Higher On 'Promising Contender' In Cancer Immunotherapy Investor's Business Daily
07:05AM  Today's Research Reports on Trending Tickers: Heron Therapeutics and Bristol-Myers Squibb ACCESSWIRE
Nov-11-18 08:13PM  How Bristol-Myers Squibb Company Fell $18.8 Billion in October Motley Fool
Nov-09-18 03:17PM  Catalyst (CPRX) Reports Q3 Loss as Expected & Pipeline Update Zacks
02:23PM  Keryx's (KERX) Loss Narrower Than Expected in Q3, Sales Lag Zacks
01:25PM  Highly Rated 'Surgeon' For Biologic-Drug Makers Soars 85% In 2018 Investor's Business Daily
08:56AM  The Zacks Analyst Blog Highlights: DXP Enterprises, Bristol-Myers Squibb, EnPro Industries, Illumina and NetApp Zacks
07:31AM  Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug Zacks
07:00AM  Today's Research Reports on Trending Tickers: AstraZeneca and Bristol-Myers Squibb ACCESSWIRE
Nov-08-18 05:45PM  Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know Zacks
01:42PM  Stada, Angelini among final bidders for $1 billion Bristol-Myers' UPSA unit - sources Reuters
01:39PM  Stada, Angelini among final bidders for $1 bln Bristol-Myers' UPSA unit - sources Reuters
01:14PM  Stada, Angelini among final bidders for $1 bln Bristol-Myers' Upsa unit - sources Reuters
11:36AM  Edited Transcript of BMY earnings conference call or presentation 25-Oct-18 2:30pm GMT Thomson Reuters StreetEvents
11:13AM  Horizon Pharma (HZNP) Q3 Earnings & Sales Beat, Shares Rise Zacks
11:07AM  Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q3 Zacks
09:39AM  Alnylam's (ALNY) Q3 Loss Narrower Than Expected, Sales Miss Zacks
08:14AM  Democrats Hold Edge in House Battle: 5 Great Picks (Revised) Zacks
08:09AM  Wall Street Likely to Sustain Post-Midterm Rally: 5 Picks Zacks
Nov-07-18 04:08PM  Mallinckrodt (MNK) Beats on Q3 Earnings Estimates, Ups View Zacks
10:50AM  Bristol-Myers, Infinity to Test Opdivo Combo for Bladder Cancer Zacks
09:23AM  Why Nektar Therapeutics Fell 36.5% in October Motley Fool
07:50AM  The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie Benzinga
06:59AM  Bristol-Myers Squibb to Take Part in Credit Suisse 2018 Health Care Conference Business Wire
Nov-06-18 04:34PM  U.S. Food and Drug Administration Approves Empliciti® (elotuzumab) Plus Pomalidomide and Dexamethasone, a New Immunotherapy Combination for Certain Patients with Relapsed or Refractory Multiple Myeloma Business Wire
04:31PM  Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q3 Zacks
04:30PM  Why Nektar Therapeutics Tumbled 10% Today Motley Fool
11:20AM  Beaten-Down Pharma ETFs to Buy Post Q3 Results Zacks
09:30AM  BMY vs. AZN: Which Stock Is the Better Value Option? Zacks
07:00AM  Democrats Hold Edge in House Battle: 5 Great Picks Zacks
Nov-05-18 02:25PM  Corcept (CORT) Q3 Earnings In Line, Revenues Miss Estimates Zacks
02:20PM  Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3 Zacks
07:49AM  The Zacks Analyst Blog Highlights: Newfield Exploration, Amazon.com, Bristol-Myers Squibb, Eaton and CF Industries Holdings Zacks
06:59AM  Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer PR Newswire
Nov-02-18 06:11PM  AMAG Posts Wider-Than-Expected Q3 Loss, Beats on Revenues Zacks
Nov-01-18 05:13PM  Bristol-Myers Squibb plans layoffs of ZymoGenetics' remaining Seattle-area employees American City Business Journals
04:56PM  Novo Nordisk (NVO) Reports In-Line Q3 Earnings, Beats Sales Zacks
04:50PM  Zoetis (ZTS) Beats on Q3 Earnings & Sales, Updates '18 View Zacks
Oct-31-18 02:52PM  The Pharmaceuticals Industry Stock Outlook: A Steady Path Ahead Zacks
08:17AM  Zacks.com highlights: Bristol-Myers Squibb, United Rentals, Capital One Financial and Harris Zacks
08:01AM  The Zacks Analyst Blog Highlights: ArcBest, Express, Arch Coal, Bristol-Myers Squibb and Methanex Zacks
Oct-30-18 10:28AM  Is Halloween the Best Time to Invest? 5 Solid Buys Zacks
Oct-29-18 07:27PM  Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know Zacks
05:48AM  The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers (Revised) Zacks
Oct-26-18 11:39AM  Pharma Stock Roundup: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO Zacks
Oct-25-18 06:55PM  Bristol-Myers Squibb Co (BMY) Q3 2018 Earnings Conference Call Transcript Motley Fool
02:25PM  Pharma Giants Merck, Bristol Diverge On Earnings Beat As Sales Lag Investor's Business Daily
11:44AM  Merck and Bristol-Myers Squibb Are Seeing Rising Sales of Their Cancer Drugs Barrons.com
11:37AM  Bristol-Myers (BMY) Beats on Q3 Earnings, Raises EPS View Zacks
10:43AM  Merck, Bristol-Myers profits rise on cancer drug sales Reuters
09:34AM  Bristol-Myers Beats Q3 Earnings, Boosts Full-Year Outlook on Solid Opdivo Sales TheStreet.com
09:15AM  Why Bristol-Myers Squibb (BMY) is a Top Dividend Stock for Your Portfolio Zacks
08:30AM  A Spotlight On Bristol-Myers Squibb Companys (NYSE:BMY) Fundamentals Simply Wall St.
08:25AM  Bristol-Myers Squibb (BMY) Q3 Earnings Beat Estimates Zacks
08:00AM  Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology PR Newswire
07:38AM  Bristol-Myers: 3Q Earnings Snapshot Associated Press
07:18AM  Bristol-Myers stock rises 2.4% after Q3 profit beat, upbeat 2018 guidance MarketWatch
07:01AM  [$$] Bristol-Myers Squibb Raises Full-Year Profit Forecast The Wall Street Journal
06:59AM  Bristol-Myers profit rises on better-than-expected cancer drug sales Reuters
06:59AM  Bristol-Myers Squibb Reports Third Quarter Financial Results Business Wire
Oct-24-18 02:45PM  Bristol-Myers Squibb Q3 Earnings Outlook Benzinga
09:33AM  Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG Zacks
Oct-23-18 11:04AM  Bristol-Myers Declines, FDA Delays Review of Opdivo for NSCLC Zacks
07:36AM  The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers Zacks
Oct-22-18 07:54PM  [$$] Bristol-Myers Faces a Costly Delay The Wall Street Journal -6.30%
05:48PM  Why Nektar Therapeutics Crashed 17.2% Today Motley Fool
04:49PM  Mirati Shares Fall After Cancer Trial Progress Report TheStreet.com
04:45PM  Biotech Dives After Lung Cancer Regimen With Bristol Disappoints Investor's Business Daily
04:25PM  MarketPulse: Healthcare Slips as Bristol-Myers Squibb Sinks Investing.com
04:20PM  Bristol-Myers Slides After FDA Delays Marketing Approval for Cancer Therapy TheStreet.com
04:03PM  Dow Trades Lower After Momentum From China Rally Fades, Nasdaq Rises TheStreet.com
01:47PM  Will Bristol-Myers move higher? Is Activision Blizzard ov... CNBC Videos
01:03PM  [$$] Bristol-Myers Faces a Costly Delay The Wall Street Journal
11:51AM  Why Mirati Therapeutics Inc. Is Plunging Today Motley Fool
10:37AM  Mirati Therapeutics stock drops 19.5% after cancer trial results MarketWatch
10:36AM  Bristol-Myers Squibb stock drops 6% after FDA delays approval deadline for cancer drug MarketWatch
08:35AM  Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings? Zacks
07:10AM  Are Bristol-Myers Squibb Companys (NYSE:BMY) Interest Costs Too High? Simply Wall St.
06:45AM  Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Results in Significantly Longer Treatment-Free Survival in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Business Wire
03:20AM  Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Durable Four-Year Survival Benefits in Patients with Advanced Melanoma Business Wire
03:15AM  Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Durable Clinical Benefit in Previously Untreated Patients with MSI-H or dMMR Metastatic Colorectal Cancer Business Wire
Oct-20-18 03:15AM  Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Shows Promising Results in Patients with Advanced Form of Bladder Cancer Business Wire
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The company has collaboration agreements with Nektar Therapeutics; Illumina, Inc.; Janssen Pharmaceuticals, Inc.; Advantagene, Inc.; Compugen Ltd.; Infinity Pharmaceuticals, Inc.; and Tsinghua University, as well as a research partnership with Sirenas. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Biondi PaulSVP, Head of Strategy & BDOct 02Option Exercise0.005920592Oct 04 04:56 PM
Dubow AdamChief Compliance & Ethics OffiSep 03Option Exercise0.00797015,495Sep 05 04:49 PM
Santiago Karen MurphyControllerSep 01Option Exercise0.0064104,057Sep 05 04:49 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510050,168Aug 03 05:05 PM
Biondi PaulSVP, Head of Strategy & BDJul 01Option Exercise0.001,46101,461Jul 03 09:24 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400292,822May 08 05:05 PM
Paliwal Dinesh CDirectorApr 30Buy52.404,770249,9488,027May 02 04:05 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerApr 03Option Exercise0.0012,367018,267Apr 05 04:37 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00219,2110333,970Mar 13 04:56 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0036,044075,370Mar 13 04:56 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,043086,932Mar 13 04:56 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0034,681053,132Mar 13 04:57 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0039,235062,028Mar 13 04:55 PM
Santiago Karen MurphyControllerMar 10Option Exercise0.004,40704,456Mar 13 04:55 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0091,3180363,739Mar 13 04:53 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,2750136,441Mar 13 04:54 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0068,8960488,677Mar 13 04:54 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 23Option Exercise22.1437,460829,364302,348Feb 27 04:45 PM
Samuels Theodore R. IIDirectorDec 15Buy62.304,000249,18722,000Dec 18 04:21 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerDec 12Sale63.245,300335,1729,251Dec 13 05:31 PM
LEUNG SANDRAEVP, General CounselDec 04Option Exercise22.14156,5823,466,725584,373Dec 05 06:15 PM
LEUNG SANDRAEVP, General CounselDec 04Sale63.37156,5829,922,601427,791Dec 05 06:15 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010267,770Dec 05 06:15 PM